Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...
What if a person with high blood pressure did not take ... We do have patients who are seeing results on lower doses.” People taking semaglutide, he emphasized, “really have to eat slow ...